Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CNS Pharmaceuticals, Inc.CNSP · Entity 8048 | CEO and President | August 14, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CNS Pharmaceuticals, Inc.
Report date August 14, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,750 |
Reported balance
After 2026-08-14 transaction · row 1
1 source rowRow 1 · 2026-08-14 · Exercise / conversion · Disposed 4,750 · Balance 4,750 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 14,250 |
Reported balance
After 2026-08-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-14 · Exercise / conversion · Disposed 4,750 · Balance 14,250 F1: Each restricted stock unit represents a contingent right to receive one share of Company common stock. F3: Issued in connection with the reporting person's employment with the Company. F2: On January 1, 2026, the reporting person was granted 19,000 restricted stock units, vesting as follows: 25% on the six-month anniversary of the grant date, 25% on the twelve-month anniversary of the grant date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Company common stock.
F2: On January 1, 2026, the reporting person was granted 19,000 restricted stock units, vesting as follows: 25% on the six-month anniversary of the grant date, 25% on the twelve-month anniversary of the grant date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date.
F3: Issued in connection with the reporting person's employment with the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 18, 2026 13:00 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | Exercise / conversionRestricted Stock Units · Derivative | 4,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-26-006552 · ownership.xml · derivative · entry 2 Levin Rami · CIK 0002102719 · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 4,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Company common stock. F3 · price: Issued in connection with the reporting person's employment with the Company. F2 · derivative.exercise_date: On January 1, 2026, the reporting person was granted 19,000 restricted stock units, vesting as follows: 25% on the six-month anniversary of the grant date, 25% on the twelve-month anniversary of the grant date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date. F2 · derivative.expiration_date: On January 1, 2026, the reporting person was granted 19,000 restricted stock units, vesting as follows: 25% on the six-month anniversary of the grant date, 25% on the twelve-month anniversary of the grant date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date. F2 · balance_after: On January 1, 2026, the reporting person was granted 19,000 restricted stock units, vesting as follows: 25% on the six-month anniversary of the grant date, 25% on the twelve-month anniversary of the grant date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date. Read SEC document |
| August 14, 2026 Filed Aug 18, 2026 13:00 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | Exercise / conversionCommon Stock | 4,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-26-006552 · ownership.xml · nonDerivative · entry 1 Levin Rami · CIK 0002102719 · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 01, 2026 Filed Jan 2, 2026 22:01 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantRestricted Stock Units · Derivative | 19,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-26-000016 · ownership.xml · derivative · entry 1 Levin Rami · CIK 0002102719 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2036-01-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Company common stock. F3 · price: Issued in connection with the reporting person's employment with the Company. F2 · derivative.exercise_date: The restricted stock units set forth in the table vest as follows: 25% on the six-month anniversary of the transaction date, 25% on the twelve-month anniversary of the transaction date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.